Promoters hold 72.85% stake in Modern Diagnostic

Modern Diagnostic & Research Centre Limited has submitted its yearly disclosure to BSE Limited under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The filing, dated April 5, 2026, details the shareholding status of the company's promoters for the financial year ended March 31, 2026.

Promoter Shareholding Details

The disclosure confirms that the members of the promoter and promoter group, including persons acting in concert, collectively hold 1,09,99,978 equity shares. This stake represents 72.85% of the total shareholding of Modern Diagnostic & Research Centre Limited .

Encumbrance Status

In the declaration submitted to the stock exchange, the promoters explicitly stated that they have not created any encumbrance on these shares during the financial year ended March 31, 2026. This confirmation covers both direct and indirect holdings of the promoter group.

Shareholder Category	Number of Shares	Percentage of Shareholding
Promoter and Promoter Group	1,09,99,978	72.85%

The disclosure was signed by Devender Singh Yadav, Promoter & Managing Director, and Priyanshu Yadav, Company Secretary & Compliance Officer. The document has been submitted for the record of BSE Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	-7.91%	-7.79%	-25.26%	-25.26%	-25.26%

Modern Diagnostic & Research Centre Limited convened a Board of Directors meeting on May 13, 2026, during which several significant resolutions were considered and approved. The meeting commenced at 11:03 A.M. and concluded at 11:17 A.M., covering matters related to IPO proceeds utilization, working capital funding, and a discussion on system disruptions.

Key Resolutions Approved

The board addressed three principal agenda items during the meeting. The following table summarizes the matters considered and approved:

Agenda Item:	Details
IPO Proceeds Utilization:	Approved extension of time for utilization of net issue proceeds and completion of project as stated in the prospectus
Working Capital Funding:	Approved utilization of funds under General Corporate Purpose (GCP) for working capital requirements
System Faults Discussion:	Discussion regarding faults in the company's hardware and software systems causing temporary shutdown, subsequently restored/recovered

Extension of Net Issue Proceeds Utilization

The board approved a resolution granting an extension of time for the utilization of net issue proceeds and the completion of the project as outlined in the company's prospectus. This resolution reflects the board's intent to align project timelines with the originally stated objectives under the applicable regulatory framework.

Working Capital Allocation Under GCP

In a related resolution, the board approved the utilization of funds earmarked under the General Corporate Purpose (GCP) head for working capital requirements. This decision enables the company to deploy a portion of its raised funds toward meeting its operational funding needs.

Hardware and Software System Disruptions

As part of the any other business agenda, the board discussed faults in the company's hardware and software systems. These faults resulted in an unexpected shutdown of certain systems for a temporary period. The board noted that the affected systems were subsequently restored and recovered. The matter was discussed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring timely disclosure to stakeholders.

Regulatory Compliance

The board meeting outcome was communicated to BSE Limited in compliance with Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Devendra Singh Yadav, Managing Director (DIN: 01254395), on May 13, 2026.